NEW YORK (GenomeWeb News) – Pressure BioSciences and Omni International today announced that they have entered into a marketing, distribution, and technology co-development pact for their respective sample preparation technologies.
Under the deal, the firms agreed to share market data, customer leads, technology assessments, and competitive information. They also will co-promote certain products at industry trade shows beginning next year and co-develop new instruments and consumables that combine Omni’s homogenization capabilities with Pressure Bio’s extraction capabilities.
Pressure Bio also granted Marietta, Ga.-based Omni a license to sell its PCT Shredder, a device that extracts nucleic acids, proteins, lipids, and small molecules from samples, to laboratories worldwide.
“We believe that combining the advantages of both technologies could offer the customer a range of solutions to ensure efficient extraction for many sample types, particularly those that continue to pose challenges in sample preparation,” Karl Jahn, president of Omni, said in a statement.
Jahn also disclosed that his firm will participate in a planned financing for South Easton, Mass.-based Pressure Bio, which recently said that it is actively seeking to raise additional capital.
Pressure Bio recently announced a restructuring that will include the reduction of eight positions at the firm and the closure of its R&D facility in Rockville, Md.